Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
3(15%)
Results Posted
0%(0 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_4
9
45%
Ph phase_2
2
10%
Ph phase_3
5
25%
Ph not_applicable
3
15%

Phase Distribution

0

Early Stage

2

Mid Stage

14

Late Stage

Phase Distribution19 total trials
Phase 2Efficacy & side effects
2(10.5%)
Phase 3Large-scale testing
5(26.3%)
Phase 4Post-market surveillance
9(47.4%)
N/ANon-phased studies
3(15.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

3

trials recruiting

Total Trials

20

all time

Status Distribution
Active(6)
Completed(7)
Terminated(2)
Other(5)

Detailed Status

Completed7
unknown4
Not yet recruiting3
Recruiting2
Active, not recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
3
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (10.5%)
Phase 35 (26.3%)
Phase 49 (47.4%)
N/A3 (15.8%)

Trials by Status

active_not_recruiting15%
unknown420%
suspended15%
withdrawn15%
completed735%
recruiting210%
terminated15%
not_yet_recruiting315%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT07405671Phase 4

Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation

Not Yet Recruiting
NCT07270848Phase 4

Dronedarone Rhythm Intervention for Early Atrial Fibrillation

Not Yet Recruiting
NCT04837261

Shortening Duration of Antiarrhythmic Medication for SVT in Infants

Completed
NCT02347111Phase 4

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Recruiting
NCT05631730Phase 3

Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse

Recruiting
NCT06205550Phase 2

N-of-1 in ATS and MEPPC

Not Yet Recruiting
NCT06142604Phase 4

Single Dose Flecainide for Early Sinus Rhythm Conversion of Perioperative Atrial Fibrillation After Noncardiac Surgery

Withdrawn
NCT05213104Phase 3

Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia

Active Not Recruiting
NCT03005366Phase 4

Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents

Completed
NCT00408473Phase 4

Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.

Terminated
NCT03587558Phase 4

Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract

Unknown
NCT02294955Not Applicable

Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)

Unknown
NCT00000526Phase 3

Cardiac Arrhythmia Suppression Trial (CAST)

Completed
NCT00000556Phase 3

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

Completed
NCT02110537Not Applicable

Acupuncture in Persistent Atrial Fibrillation

Unknown
NCT00215774Not Applicable

Flecainide-Short Long Study (Flec-SL)

Completed
NCT01646281Phase 4

Vernakalant Versus Flecainide: Atrial Contractility

Unknown
NCT00000504Phase 2

Cardiac Arrhythmia Pilot Study (CAPS)

Completed
NCT00702117Phase 4

Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias

Completed
NCT00392106Phase 3

High Intensity Focused Ultrasound (HIFU) Ablation System Study

Suspended

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20